Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

CAMBRIDGE, Mass., April 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2009. At March 31, 2009, Idenix's cash, cash equivalents and marketable securities totaled $64.5 million.

Business Highlights

  • In the first quarter of 2009, the company announced that it had licensed its NNRTI program for the treatment of HIV/AIDS, including IDX899, to GlaxoSmithKline (GSK) and received a $34 million payment, $17 million of which was a cash payment and the other $17 million representing the purchase of shares of Idenix common stock by GSK. Idenix may also be eligible to receive up to $416 million in development, regulatory and sales milestones, as well as double-digit tiered royalties based on worldwide product sales.
  • In April 2009, data were presented from each of Idenix's hepatitis C programs at the annual meeting of the European Association for the Study of the Liver in Copenhagen, Denmark (see press release dated April 23, 2009 for further details). The company continues to advance its three HCV discovery and development programs, with a nucleoside/tide polymerase inhibitor being evaluated in a proof-of-concept clinical study and non-nucleoside polymerase and protease inhibitors undergoing late-stage preclinical testing.

"Our primary objective at Idenix is to discover and develop the leading HCV antiviral platform," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "With the licensing of IDX899 to GSK in February of this year and the continued advancement of drug candidates from three major classes of
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... PRC Clinical, the Clinical Trial ... Regenerative Medicine (ARM). The ARM counts more than ... commercialization of transformational treatments and cures for patients ... CRO focused in Clinical Trial Management, has developed ... research working with sponsors in the United States ...
(Date:5/25/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. Major companies ... Linde Industrial Gas, Basf, Air Products, Air Liquide, ... Longsheng Group, Juhua Group, Wandali Gas, Unid(Jiangsu) Chemical, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Charm ... U.S. Department of Agriculture (USDA), Grain Inspection, Packers ... year contract to Charm Sciences to monitor aflatoxin ... Test (water-based) and ROSA FAST Aflatoxin Quantitative Test ... Quantitative Test uses Water Extraction Technology to ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Seventh Wave ... safety and efficacy of pharmaceutical products and medical devices, ... Heights, MO 63043, a 50,000 sq. ft. building more ... to enable strategic growth. Facility renovations will begin immediately ... new space will occur in September. , “We ...
Breaking Biology Technology:PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3
... team of U.S., Israeli and German scientists used computational ... role in human cell division and to identify more ... pattern of activation in cancer cells., Malignant cells have ... in cell cycle gene activation in normal and malignant ...
... ... Patients, CAMBRIDGE, ... ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ),announced today that ... and commercialize mipomersen, Isis, lipid-lowering,treatment for high risk cardiovascular patients that ...
... Wins for Industry Leadership, JOPLIN, Mo., Jan. ... announced its Medical Power group has received,Battery Power ... received honors in the Industry Leadership category for ... battery., The Innova Award recognizes companies that ...
Cached Biology Technology:International team identifies 480 genes that control human cell division 2International team identifies 480 genes that control human cell division 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7EaglePicher Technologies Receives Battery Power Products and Technology's First Annual Innova Award 2
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... 10, 2011The mega-mergers of 2009 did not continue into 2010. ... price tag of more than $40 billion, only last year,s ... of reported deals conducted by Genetic Engineering & Biotechnology News ... the year, sanofi-aventis, move to buy Genzyme, is still being ...
... reports that several herbicides used on corn also have ... Miscanthus), a potential bioenergy feedstock. "No herbicides are ... biomass," said Eric Anderson, an instructor of bioenergy for ... of Illinois. "Our research shows that several herbicides used ...
... 20,000 to 30,000 genes (the number is hotly contested), but ... proteins. It,s the protein molecules that domost of the work ... from the Greek prota, meaning "of primary importance." Proteins ... of usually fold spontaneously into what is called their "native ...
Cached Biology News:GEN reports on biotech acquisition deals in 2010 that topped $1 billion 2Miscanthus has a fighting chance against weeds 2New method takes snapshots of proteins as they fold 2New method takes snapshots of proteins as they fold 3New method takes snapshots of proteins as they fold 4New method takes snapshots of proteins as they fold 5
...
... T7 Phage Capture Plate is a 96-well ELISA-compatible ... the T7 Tail Fiber Monoclonal Antibody is immobilized ... The antibody specifically recognizes the tail fiber protein ... has a capacity of 10 9 phage ...
... TRAPeze RT Telomerase Detection Kit ... vitro assay for the fluorometric ... of telomerase activity. It incorporates ... assay and adds the ability ...
... The expertise that made the original Gene Pulser ... system available has been applied in the Gene ... The modular design of the Gene Pulser II ... accessory that has the widest range of settings ...
Biology Products: